In the face of unprecedented cost-per-patient expenses, the FDA's recent focus on rare disease, and a myriad of options for identifying, engaging, screening, and retaining eligible patients, it is essential to prioritize patient-centric recruitment strategies. As the landscape of rare disease research undergoes a transformative shift, by placing the patient at the heart of recruitment efforts, we can effectively address the significant unmet medical needs in rare diseases and streamline the pathway to innovative treatments.

The Patient Recruitment for Rare Disease Trials Summit serves as the premier event for experts in patient recruitment, advocacy and clinical operations to unite in order to navigate cost-efficient, patient centric recruitment to expedite enrolment in rare disease trials. Don't miss the chance to collaborate with industry experts working towards a common goal: ensuring that patients with rare diseases have access to life-changing therapies.


URLs:
Tickets: https://go.evvnt.com/2563753-1?pid=91
Brochure: https://go.evvnt.com/2563753-2?pid=91

Prices:
Industry Pricing - (Conference + 2 Workshops): USD 4197.00,
Industry Pricing - (Conference + 1 Workshop): USD 3598.00,
Industry Pricing - (Conference Only): USD 2999.00,
Discounted Pricing - (Conference + 2 Workshops): USD 3597.00,
Discounted Pricing - (Conference + 1 Workshop): USD 3597.00,
Discounted Pricing - (Conference Only): USD 3098.00,
Vendor Pricing - (Conference + 2 Workshops): USD 5097.00,
Vendor Pricing - (Conference + 1 Workshop): USD 4398.00,
Vendor Pricing - (Conference Only): USD 3699.00

Speakers: Alayna Tress, Associate Director, Patient Advocacy, PepGen, Amanda Rohrig, Director, Patient Advocacy, BridgeBio, Bethany Firem, Associate Director, Global Patient Affairs, BioMarin Pharmaceutical, Christine Brown, Associate Director, Patient Partnerships, Astellas Pharma, Ella Balasa, Patient Advocacy and Engagement Consultant, Independent, Heidi Floyd, Patient Advocate, National Coalition for Cancer Survivorship, Ify Osunkwo, Chief Patient Officer, Rare Disease, Novo Nordisk, Jennifer Gaskin, Senior Director, Clinical Operations, Celldex Therapeutics, Jessica Klein, Director, Global Rare Disease Awareness, Ipsen, Kelli Wright Director, Patient Advocacy, Day One Biopharmaceuticals, Lauren Powell, Head, Health Equity, Biogen, Lori Correia, Patient Advocacy Consultant, Tenaya Therapeutics, Monique Mulkern, Head, Global Patient Insights and Solutions, Alexion Pharmaceuticals, Ross Heiney, Ultra-Rare Patient Access and Field Reimbursement, Reata Pharmaceuticals, Tara Hastings, Global Patient Engagement Lead, Sanofi